Table 7: Percentage of subjects with hSBA titres ≥1 : 8 and hSBA GMTs against serogroups A, C, W-135, and Y at 42 days after one dose of MenACWY-TT in toddlers (ATP immunogenicity cohort).

Vaccine 𝑁 %  ≥ 1 : 8 [95% CI]GMT [95% CI]

hSBA-MenA

MenACWY-TT33877.2 [72.4–81.6]19.0 [16.4–22.1]
MenACWY-TT + MMRV34883.9 [79.6–87.6]33.7 [28.9–39.2]

hSBA-MenC

MenACWY-TT34198.5 [96.6–99.5]196.0 [175.4–219.0]
MenACWY-TT + MMRV34698.0 [95.9–99.2]209.1 [183.8–238.0]
MenC-CRM19711681.9 [73.7–88.4]40.3 [29.5–55.1]

hSBA-MenW-135

MenACWY-TT33687.5 [83.5–90.8]48.9 [41.2–58.0]
MenACWY-TT + MMRV33782.8 [78.3–86.7]57.3 [47.0–69.9]

hSBA-MenY

MenACWY-TT32979.3 [74.5–83.6]30.9 [25.8–37.1]
MenACWY-TT + MMRV33381.4 [76.8–85.4]38.7 [32.2–46.7]

𝑁 : numbers of subjects with available data, %: percentage of subjects with titre within the specified range, 95% CI: 95% confidence interval, GMT: Geometric Mean Titre, Results of this table were previously published [90].